GlassScriptPhysician profile
Paresh D Patel
NPI 1508022484
$24,681.27
in general payments reported to CMS, 2019-2025
45 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $248 · 2021: $7,510 · 2022: $1,298 · 2023: $1,234 · 2024: $1,586 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.33 |
| Education | $213.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,088.49 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Glaxosmithkline, LLC. | $7,224.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,781.98 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Actelion Pharmaceuticals US, INC. | $881.35 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Electromed, INC. | $876.31 | 2019-2024 | Smartvest |
| Pulmonx Corporation | $382.50 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genentech USA, INC. | $352.87 | 2019 | |
| Jazz Pharmaceuticals INC. | $318.49 | 2019-2025 | |
| Harmony Biosciences LLC | $266.32 | 2021-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $232.39 | 2019-2023 | Xarelto |
| Philips North America LLC | $218.38 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Shionogi INC | $218.11 | 2022-2025 | Fetroja |
| Mylan Specialty L.P. | $216.97 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $195.88 | 2022-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $195.78 | 2023-2025 | Sunosi |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $193.33 | 2019-2025 | Dupixent |
| Cvrx, INC. | $175.89 | 2023 | Barostim Neo System |
| Insmed, INC. | $175.13 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $168.71 | 2019-2025 | Tavneos, Tezspire |
| Genzyme Corporation | $147.57 | 2019-2024 | |
| Zoll Respicardia, INC. | $144.48 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $140.44 | 2024-2025 | Lumryz |
| Baxter Healthcare | $137.83 | 2024 | Perclot |
| United Therapeutics Corporation | $135.16 | 2019-2024 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $103.17 | 2022-2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $98.45 | 2019-2020 | |
| Pinnacle Biologics, INC | $71.95 | 2024 | Photofrin |
| Optinose US, INC. | $71.17 | 2021-2022 | |
| Boston Scientific Corporation | $59.78 | 2023-2025 | Bodyguardian |
| Olympus America INC. | $54.68 | 2020-2022 | |
| Resmed Corp | $50.80 | 2019 | |
| Esperion Therapeutics, INC. | $48.69 | 2023-2024 | Nexletol |
| Circassia INC. | $44.10 | 2019-2020 | |
| Inspire Medical Systems, INC. | $36.74 | 2023 | Inspire |
| 3b Medical, INC. | $29.18 | 2023 | Luna |
| Kaleo, INC. | $22.00 | 2020 | |
| Chiesi USA, INC. | $18.77 | 2024 | Kengreal |
| Medtronic Vascular, INC. | $16.78 | 2019 | |
| Verona Pharma, INC. | $16.20 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $15.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.35 | 2019 | |
| Ekos Corporation | $13.76 | 2019 | |
| Gilead Sciences, INC. | $13.58 | 2019 | |
| Advanced Respiratory, INC | $13.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.